Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
Abstract Background One of the functions of the reformed Cancer Drugs Fund in England is as a managed access fund, providing conditional funding for cancer drugs where there is uncertainty in the economic case, and where that uncertainty can be addressed by data collection during two years' use...
Saved in:
Main Authors: | Liz Morrell (Author), Sarah Wordsworth (Author), Anna Schuh (Author), Mark R. Middleton (Author), Sian Rees (Author), Richard W. Barker (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2018-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
by: Liz Morrell, et al.
Published: (2019) -
Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
by: Liz Morrell, et al.
Published: (2017) -
Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis
by: George Hale, et al.
Published: (2023) -
The Challenges of Measuring and Valuing Quality of Life in Preschool Children: A Retrospective Review of NICE Appraisals
by: Alan Lamb, et al.
Published: (2021) -
Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023)